Relative Strength Chart Protagonist Therapeutics, Inc.

Equities

Market Closed - Nasdaq Other stock markets 16:00:00 2025-12-12 EST			5-day change	1st Jan Change
95.35 ^USD	+3.36%		+6.36%	+147.02%

12-06	Protagonist Therapeutics, Inc. and Takeda Pharmaceutical Company Limited Present Longer-Term Data At ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera	CI
11-06	Protagonist Therapeutics Q3 net loss widens to $39.3 mln	RE

End-of-day quotes

		Sector	Change	5d. change	Varia. Jan 1.	1-year change	5-years change	Capi.	ST	MT	LT
	PROTAGONIST THERAPEUTICS, INC.	Other Biotechnology & Medical Research	+3.36%	+6.36%	+147.02%	+132.11%	+343.08%	5.96B